The current financial score of Palisade Bio Inc is 6.59. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Palisade Bio Inc is 8.88. Its current P/E ratio is 14.35, which is 31.95% below the recent high of 18.93 and 164.74% above the recent low of -9.29.
The current earnings forecast score of Palisade Bio Inc is 8.80. The average price target is 10.40, with a high of 25.00 and a low of 5.00.
The current price momentum score of Palisade Bio Inc is 4.90. Currently, the stock price is trading between the resistance level at 2.09 and the support level at 1.44, making it suitable for range-bound swing trading.
The current institutional shareholding score of Palisade Bio Inc is 7.00. The latest institutional shareholding proportion is 82.61%, representing a quarter-over-quarter increase of 79.95%.
The current risk assessment score of Palisade Bio Inc is 4.52. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.